Surrozen Inc., a San Francisco, CA-based biopharmaceutical company, secured $50m in Series B financing.
Backers included Horizons Ventures, Hartford HealthCare Endowment, NS Investment and the Column Group.
Proceeds from the financing will be used to advance the company’s antibody discovery and development programs in liver disease, and to expand its therapeutic platform into additional disease areas where Wnt modulation has therapeutic potential.
Led by Craig Parker, CEO, Surrozen is a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway. The company has developed two proprietary antibody platforms that can function as Wnt or R-spondin mimetics, respectively, in stimulating cell and organ-specific tissue regeneration.
Surrozen has also expanded its Board of Directors with the appointment of Anna Berkenblit, MD, as a Director. Dr. Berkenblit is currently Senior Vice President and Chief Medical Officer at Immunogen and has extensive experience in clinical development. She was previously Senior Vice President, Clinical Development, at H3 Biomedicine, and Vice President, Head of Clinical Research, at AVEO Oncology.